Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Fineline Cube Jun 30, 2026
Company Deals

Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China

Fineline Cube Jun 30, 2026
Company Deals

Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline

Fineline Cube Jun 30, 2026
Company Deals

Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration

Fineline Cube Jun 30, 2026
Company Deals

Merck Partners with ADAP Crisis Task Force to Expand Access to Idvynso HIV Treatment – Two-Drug Regimen Targets Virologically Suppressed Patients

Fineline Cube Jun 30, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

Fineline Cube Jun 30, 2026
Company Drug

AbbVie and Genmab’s Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial – 60% Reduction in Progression/Death Risk vs Standard R-GemOx

Fineline Cube Jun 30, 2026
Company Deals

ACROBiosystems Partners with OBiO Technology to Advance Cell and Gene Therapy

Fineline Cube Jul 28, 2023

ACROBiosystems Group (SHE: 301080) has announced a partnership with China-based gene therapy specialist OBiO Technology...

Company Deals

Lucence and Innovent Biologics Partner to Enhance Access to Cholangiocarcinoma Treatment in Hong Kong

Fineline Cube Jul 28, 2023

Singapore-based precision medicine specialist Lucence, with a presence in Suzhou, Hong Kong, and Palo Alto...

Company Medical Device

Beijing Balance Medical’s Transcatheter Valve System Enters China’s Innovative Device Review

Fineline Cube Jul 28, 2023

China’s Beijing Balance Medical Technology Co., Ltd (SHA: 688198) has announced that its transcatheter valve...

Company Drug

Eli Lilly’s Tirzepatide Demonstrates Up to 26.6% Weight Loss in Phase III Obesity Studies

Fineline Cube Jul 28, 2023

US pharmaceutical major Eli Lilly & Co., (NYSE: LLY) has released final results from two...

Policy / Regulatory

CDE Issues Guiding Principles for Natural History Research in Rare Disease Drug Development

Fineline Cube Jul 28, 2023

The Center for Drug Evaluation (CDE) has released the “Guiding Principles for Natural History Research...

Company Drug

Sino Biopharmaceutical Receives NMPA Approval for Biosimilar Herceptin for HER2+ Cancers

Fineline Cube Jul 28, 2023

Sino Biopharmaceutical Ltd (HKG: 1177) has announced that it has received market approval from the...

Policy / Regulatory

CDE Launches Technical Guidelines to Emphasize Patient-Centered Drug Clinical Trials

Fineline Cube Jul 28, 2023

The Center for Drug Evaluation (CDE) has released a series of Technical Guidelines that encompass...

Company Drug

Eli Lilly’s Donanemab Shows Significant Slowdown in Alzheimer’s Disease Progression in Phase III Study

Fineline Cube Jul 28, 2023

US pharmaceutical major Eli Lilly and Company (NYSE: LLY) has revealed the complete results of...

Company Drug

Jiangsu Simcere Pharmaceutical Receives NMPA Approval for Atopic Dermatitis Drug SIM0278

Fineline Cube Jul 28, 2023

China’s Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has announced that it has received clinical...

Company Deals Policy / Regulatory

Pingshan District and Fosun Pharma Ink Strategic Deal to Boost Biomedical Industry

Fineline Cube Jul 28, 2023

The People’s Government of Pingshan District in Shenzhen has signed a cooperation framework agreement with...

Company Drug

CanSino Biotechnology Receives NMPA Approval for Tetanus Vaccine CS-2047

Fineline Cube Jul 28, 2023

China-based vaccines specialist CanSino Biotechnology Inc., (HKG: 6185) has announced that it has received clinical...

Company Deals

SanReno Therapeutics Partners with WuXi STA for Comprehensive R&D and Manufacturing Services

Fineline Cube Jul 28, 2023

Shanghai-based kidney drug developer SanReno Therapeutics has entered into a partnership with WuXi STA, a...

Company Deals

Chongqing Zhifei Biological Partners with PT Bio Farma for Global Tuberculosis Vaccine Development

Fineline Cube Jul 28, 2023

China-based Chongqing Zhifei Biological Co., Ltd (SHE: 300122) has entered into a global cooperation memorandum...

Company Drug

BRL Medicine Inc. Receives IND Approval for CD19-Targeted CAR-T Therapy BRL-301 from CDE

Fineline Cube Jul 28, 2023

Shanghai-based BRL Medicine Inc. has announced that it has received Investigational New Drug (IND) approval...

Company

Bristol-Myers Squibb Q2 2023 Results Miss Estimates, Full-Year Guidance Revised Downward

Fineline Cube Jul 28, 2023

US pharmaceutical company Bristol-Myers Squibb (BMS; NYSE: BMY) has released its financial report for the...

Company

Pfizer Announces Leadership Shake-Up with Focus on Oncology R&D

Fineline Cube Jul 28, 2023

Pfizer Inc., (NYSE: PFE) has announced significant changes in its Research and Development (R&D) leadership....

Company

Roche Group’s H1 2023 Financial Report: Pharmaceuticals Grow While Diagnostics Dip

Fineline Cube Jul 28, 2023

Swiss pharmaceutical giant Roche Group (SWX: ROG) has released its half-yearly financial report for 2023,...

Company Drug

MSD’s V116 Vaccine Shows Superior Immune Response in Phase III Trials

Fineline Cube Jul 28, 2023

Merck, Sharp & Dohme (MSD; NYSE: MRK) has revealed positive topline results from two Phase...

Company Deals

Pharmaniaga Berhad and CSPC Pharmaceutical Group Broaden Collaboration in Pharma and Biopharma

Fineline Cube Jul 27, 2023

Malaysia-based pharmaceutical company Pharmaniaga Berhad has announced the signing of a comprehensive collaboration with China’s...

Company

Thermo Fisher Scientific Reports Q2 2023 Revenue Dip, Adjusts Full-Year Forecast

Fineline Cube Jul 27, 2023

US-based life sciences giant Thermo Fisher Scientific Inc. (NYSE: TMO) has released its financial results...

Posts pagination

1 … 519 520 521 … 688

Recent updates

  • METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company
  • Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China
  • Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline
  • Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications
  • Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Company Deals

Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China

Company Deals

Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline

Company Drug

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.